GAMMA Investing’s Elicio Therapeutics ELTX Stock Holding History

GAMMA Investing’s Portfolio ELTX Stock Details ELTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.84K	Buy	+1,013	New	+$2.81K	﹤0.01%	3971

Other funds holding ELTX

Shah Capital Management Raleigh, North Carolina $605M AUM 43.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

Leonteq Securities AG Zurich, Switzerland $2.44B AUM 50.17% 1-Year Est. Return

Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return

Meyer Handelman Company Rye Brook, New York $3.49B AUM 26.82% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return

Creative Planning Overland Park, Kansas $179B AUM 16.96% 1-Year Est. Return

Abel Hall LLC Baton Rouge, Louisiana $556M AUM 43.18% 1-Year Est. Return

GAMMA Investing's ELTX Position: Q3 2026 in Review

GAMMA Investing opened a new position in Elicio Therapeutics (ELTX) in Q3 2026: 1,013 shares worth $1.84K. The stake represents ﹤0.01% of the portfolio and ranks #3971 among its holdings.

27 funds tracked by Wall St. Rank hold ELTX as of Q3 2026.

GAMMA Investing held 1,013 shares of Elicio Therapeutics worth $1.84K as of Q3 2026.
Elicio Therapeutics was a new GAMMA Investing position in Q3 2026.
Elicio Therapeutics made up ﹤0.01% of GAMMA Investing's portfolio in Q3 2026, its #3971 holding.
27 funds tracked by Wall St. Rank held Elicio Therapeutics as of Q3 2026.

Based on GAMMA Investing's 13F filing for Q3 2026, filed 8 Oct 2026.